Tracers / [177Lu]Lu-DOTA-ABDB6
[177Lu]Lu-DOTA-ABDB6
Also written as [Lu-177]Lu-DOTA-ABDB6
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Nanobody-based DOTA conjugate (CD70-targeted nanobody derivative)
- Target / mechanism
- CD70 PMID 42259600
- Clinical application
- Multiple myeloma PMID 42259600
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 92.5% | >95% | DOTA-ABDB6 Biointron Biological | 42259600 2026 J Immunother Cancer For the [177Lu]Lu-labeling process, a solution of [177Lu]LuCl3 (59.2 MBq) was mixed with 200 µL of 0.25 M NaOAc (pH=5.5). — radiochemical yields of 75.6% and 92.5%, respectively |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-ABDB6, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42259600. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42259600: 'DOTA-ABDB6'.